Search
Searching Content indexed under Healthcare by LexOrbis ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
Developing Biosimilars In India: Prescriptions And Problems
In India, access to health care facilities is still limited to a very small percentage of population owing mostly to unavailability of affordable drugs and treatment.
India
6 Nov 2014
2
Resurrection For Herbal Industry
Herbal medicine is considered as the medicine of the masses and is usually referred as ‘nature medicine’. The U.S. Food and Drug Administration (FDA) has for the first time approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV).
India
10 Apr 2007
3
Publici Juris – In Pharma Products
Publici juris" is a Latin word, and in the legal parlance, means, "of public right". The term signifies a thing or a right that is open and exercisable by all persons. It designates things that belong to the entire community, and not to any private party.
India
18 Dec 2006
4
Data Exclusivity & Patents Unrelated
The seven different forms of intellectual property rights stipulated in TRIPS are patents, copyrights, trademarks, industrial designs, geographical indications, protection of IC layout design and protection of undisclosed information. Each one is independent of each other and protects different aspects of an inventive work and extends different rights to the owner.
India
7 Nov 2006
5
Data Exclusivity – TRIPS Compliant or TRIPS Plus?
Intellectual Property as such gives a right to control the activities of others and this has a number of implications, which could give rise to issues resting on delicate grounds. The theory behind the patenting system is that the financial reward flowing from the exploitation of the patent and the disclosure of the resulting inventions for public dissemination and use, would encourage innovation and raise the technical level of a nation’s industry, at the same time contributing towards to its t
India
5 Sep 2006
6
Widening Ambit Of Indian Intellectual Property Regime
The Scenario in the IPR sector has undergone vibrant change in the recent past. This change has not been restricted to the pharmaceutical sector alone, but has extended itself to other systems of Intellectual Property.
India
 
13 Jul 2006
7
Product Patenting in the Indian Pharma Sector
In the recent times the Indian pharma sector has been marked by dynamic changes. The Patent Act of 1970 as amended on March 22, 2005 marked the end of a protected era and has brought in a new phase in the integration of India into the global pharmaceutical market.
India
14 Jun 2006
8
"GLUCON-D" – Not An Exclusive Property
The Mark "GLUCON-D" was granted registration by the Indian Trade Marks Registry under registration No. 305664/30 on May 21, 1975 in relation to "Glucose (for food), Flour and Preparations Made from Cereals, Bread, Biscuits (Not for animals), Pastry and Confectionary (Non-Medicated), Milk Chocolate" in the name of Glaxo Laboratories (Indian) Limited.
India
23 Mar 2006
9
Indian Patents Law Indirectly Recognizes ‘Swiss-Type’ Claims’
Novelty is one of the basic criteria of patentability, inventiveness and industrial applicability being the other two. If the use of a substance or a composition for a specified medical purpose is new, a claim in a patent application directed at this use will be considered as novel even if the same substance had previously been used in medicine for a different purpose.
India
14 Feb 2005
10
Product Patent Regime & Pharmaceutical Industry In India - The Challenges Ahead
With the nearing of the TRIPS deadline, the pharmaceutical industry in India is gearing up to face new challenges. The product patent regime is no longer the challenge - it is a reality that the Indian pharma industry has accepted.
India
10 Jan 2005
11
Data Exclusivity – The Indian Perspective
Under Special 301 of the U.S. Trade Act of 1974 India has been put on the ‘PRIORITY WATCH LIST’ of USTR (United States Trade Representative) for failing to provide an adequate level of protection or enforcement and market access for persons relying on Intellectual Property protection.
India
21 Sep 2004
Links to Result pages
 
1